<Summary id="CDR0000800109" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>This evidence-based, expert-reviewed summary discusses the incidence, risk factors, prognosis, diagnosis, molecular features, and treatment of pediatric melanoma.</SummaryDescription><SummaryURL xref="https://www.cancer.gov/types/skin/hp/child-melanoma-treatment-pdq">Childhood Melanoma (PDQ®): Treatment</SummaryURL><SummaryToggleURL xref="https://www.cancer.gov/types/skin/patient/child-melanoma-treatment-pdq">Childhood Melanoma (PDQ®): Treatment</SummaryToggleURL><SummaryEditorialBoard ref="CDR0000028557">PDQ Pediatric Treatment Editorial Board</SummaryEditorialBoard><MainTopics><TermRef ref="CDR0000038833">melanoma</TermRef></MainTopics><SummaryAbstract><Para id="_1556">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of pediatric melanoma. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.</Para><Para id="_1557">This summary is reviewed regularly and updated as necessary by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para></SummaryAbstract><SummaryKeyWords><SummaryKeyWord>pediatric melanoma</SummaryKeyWord></SummaryKeyWords></SummaryMetaData><SummaryTitle>Childhood Melanoma Treatment (PDQ®)–Health Professional Version</SummaryTitle><AltTitle TitleType="Browser">Childhood Melanoma Treatment (PDQ®)</AltTitle><AltTitle TitleType="CancerTypeHomePage">Childhood Melanoma Treatment</AltTitle><SummarySection id="_699"><Title>Incidence</Title><Para id="_700">Melanoma is rare in children. However, it is the most common skin cancer in children, followed by
basal cell carcinomas and squamous cell carcinomas.<Reference refidx="1"/> <Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/></Para><Para id="_701">Approximately 300 cases of melanoma are diagnosed each year in patients younger than 20 years in the United States, accounting for 0.3% of all new cases of
melanoma.<Reference refidx="9"/> Melanoma accounts for about 3% of all cancers in children  aged 15 to 19 years.<Reference refidx="10"/></Para><Para id="_2463">Melanoma annual incidence in the United States increases with age, as shown in <SummaryRef href="CDR0000800109#_2483" url="/types/skin/hp/child-melanoma-treatment-pdq">Figure 1</SummaryRef> from the National Childhood Cancer Registry (NCCR).<Reference refidx="10"/> For children younger than 10 years, the incidence rate is approximately 1 to 2 cases per 1 million. During adolescence, the rates increase steadily with age, although they are much lower than those observed in adults.<Reference refidx="10"/><Reference refidx="11"/> </Para><Para id="_2480"><SummaryRef href="CDR0000800109#_2483" url="/types/skin/hp/child-melanoma-treatment-pdq">Figure 1</SummaryRef> also shows that among adolescents aged 15 to 19 years, melanoma rates are significantly higher for females (10.4 per 1 million; 95% confidence interval [CI], 9.4–11.5) than males (5.7 per 1 million; 95% CI, 5.0–6.6). Incidence rates for children younger than 15 years do not differ significantly between girls and boys. </Para><MediaLink ref="CDR0000813687" type="image/jpeg" alt="Graph showing the incidence rates of melanoma from 2016 to 2020, according to age at diagnosis. The incidence rates in males, females, and both sexes are shown." language="en" placement="image-center" id="_2483"><Caption language="en">Figure 1.  Melanoma incidence rates by age at diagnosis from 2016 to 2020. Reprinted with permission from the National Childhood Cancer Registry. NCCR*Explorer: An interactive website for NCCR cancer statistics [Internet]. National Cancer Institute; 2023 Sep 7. [updated: 2023 Sep 8; cited 2023 Dec 15]. Available from: <ExternalRef xref="https://nccrexplorer.ccdi.cancer.gov">https://nccrexplorer.ccdi.cancer.gov</ExternalRef>.</Caption></MediaLink><Para id="_1336">The incidence of pediatric melanoma (aged 0–19 years) increased by an average of 1.6% per year between 1975 and 1996. As shown in <SummaryRef href="CDR0000800109#_2484" url="/types/skin/hp/child-melanoma-treatment-pdq">Figure 2</SummaryRef>, melanoma incidence continued to increase through 2003 for adolescents (aged 15–19 years), but it subsequently dropped significantly by approximately 6% per year.<Reference refidx="10"/> During this same period, the incidence decreased slightly for children aged 0 to 14 years, but the change over time was not significant. The reason for the decline in melanoma incidence among adolescents aged 15 to 19 years is not known, but possible explanations include increased use of sunscreen and protective clothing, increased dermatological care, and reduced access to tanning beds.<Reference refidx="11"/></Para><MediaLink ref="CDR0000813686" type="image/jpeg" alt="Graph showing trends in age-adjusted incidence rates of melanoma from 1999 to 2020, in adolescents aged 15 to 19 years." language="en" placement="image-center" id="_2484"><Caption language="en">Figure 2.  Trends in melanoma age-adjusted incidence rates from 1999 to 2020 for adolescents aged 15 to 19 years. Reprinted with permission from the National Childhood Cancer Registry. NCCR*Explorer: An interactive website for NCCR cancer statistics [Internet]. National Cancer Institute; 2023 Sep 7. [updated: 2023 Sep 8; cited 2023 Dec 15]. Available from: <ExternalRef xref="https://nccrexplorer.ccdi.cancer.gov">https://nccrexplorer.ccdi.cancer.gov</ExternalRef>.</Caption></MediaLink><Para id="_2464"> A retrospective study of 22,524 skin pathology reports from patients younger than 20 years identified 38 melanomas, 33 of which occurred in patients aged 15 to 19 years. Investigators reported that the  number of lesions that needed to be excised to identify one melanoma was 479.8, which is 20 times higher than in the adult population.<Reference refidx="12"/></Para><ReferenceSection><Citation idx="1" PMID="8954269" MedlineID="97112590">Sasson M, Mallory SB: Malignant primary skin tumors in children. Curr Opin Pediatr 8 (4): 372-7, 1996.</Citation><Citation idx="2" PMID="11849894" MedlineID="21838479">Fishman C, Mihm MC, Sober AJ: Diagnosis and management of nevi and cutaneous melanoma in infants and children. Clin Dermatol 20 (1): 44-50, 2002 Jan-Feb.</Citation><Citation idx="3" PMID="12078862" MedlineID="22073156">Hamre MR, Chuba P, Bakhshi S, et al.: Cutaneous melanoma in childhood and adolescence. Pediatr Hematol Oncol 19 (5): 309-17, 2002 Jul-Aug.</Citation><Citation idx="4" PMID="7845431" MedlineID="95147937">Ceballos PI, Ruiz-Maldonado R, Mihm MC: Melanoma in children. N Engl J Med 332 (10): 656-62, 1995.</Citation><Citation idx="5" PMID="12063484" MedlineID="22058119">Schmid-Wendtner MH, Berking C, Baumert J, et al.: Cutaneous melanoma in childhood and adolescence: an analysis of 36 patients. J Am Acad Dermatol 46 (6): 874-9, 2002.</Citation><Citation idx="6" PMID="14642927">Pappo AS: Melanoma in children and adolescents. Eur J Cancer 39 (18): 2651-61, 2003.</Citation><Citation idx="7" PMID="16135138">Huynh PM, Grant-Kels JM, Grin CM: Childhood melanoma: update and treatment. Int J Dermatol 44 (9): 715-23, 2005.</Citation><Citation idx="8" PMID="16091570">Christenson LJ, Borrowman TA, Vachon CM, et al.: Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA 294 (6): 681-90, 2005.</Citation><Citation idx="9">National Cancer Institute: SEER Stat Fact Sheets: Melanoma of the Skin. Bethesda, Md: National Cancer Institute. <ExternalRef xref="https://seer.cancer.gov/statfacts/html/melan.html">Available online</ExternalRef>. Last accessed December 15, 2023.</Citation><Citation idx="10">National Cancer Institute: NCCR*Explorer: An interactive website for NCCR cancer statistics. Bethesda, MD: National Cancer Institute. <ExternalRef xref="https://NCCRExplorer.ccdi.cancer.gov/">Available online</ExternalRef>. Last accessed February 25, 2025.</Citation><Citation idx="11" PMID="31721989">Paulson KG, Gupta D, Kim TS, et al.: Age-Specific Incidence of Melanoma in the United States. JAMA Dermatol 156 (1): 57-64, 2020.</Citation><Citation idx="12" PMID="22428965">Moscarella E, Zalaudek I, Cerroni L, et al.: Excised melanocytic lesions in children and adolescents - a 10-year survey. Br J Dermatol 167 (2): 368-73, 2012.</Citation></ReferenceSection></SummarySection><SummarySection id="_702"><Title>Risk Factors</Title><Para id="_703">Conditions associated with an increased risk of developing melanoma in children and adolescents include the following:</Para><ItemizedList id="_1316" Style="bullet"><ListItem>Giant melanocytic nevi.<Reference refidx="1"/></ListItem><ListItem>Xeroderma pigmentosum. This is a rare recessive disorder characterized by extreme sensitivity to sunlight, keratosis, and various neurological manifestations.<Reference refidx="1"/>  For more information about xeroderma pigmentosum, see <SummaryRef href="CDR0000552637" url="/types/skin/hp/skin-genetics-pdq">Genetics of Skin Cancer</SummaryRef>.</ListItem><ListItem>Immunodeficiency or   immunosuppression.<Reference refidx="2"/></ListItem><ListItem>Hereditary retinoblastoma.<Reference refidx="3"/></ListItem><ListItem>Werner syndrome.<Reference refidx="4"/><Reference refidx="5"/>  </ListItem><ListItem>Neurocutaneous melanosis. This is an unusual condition that arises in the context of congenital melanocytic nevi and is associated with large or multiple congenital nevi of the skin in association with meningeal melanosis or melanoma. Approximately 2.5% of patients with large congenital nevi develop this condition, and those with increased numbers of satellite nevi are at greatest risk.<Reference refidx="6"/><Reference refidx="7"/><Para id="_2056">Patients with central nervous system (CNS) melanomas arising in the context of congenital melanocytic nevi syndrome have a poor prognosis, with a mortality rate of 100%. Most of these patients have <GeneName>NRAS</GeneName> variants. Therefore, mitogen-activated protein kinase pathway inhibitors might be used in the treatment of this disease. Four children who received a MEK inhibitor experienced transient symptomatic improvements. However, all patients eventually died of disease progression.<Reference refidx="8"/> A German registry identified five children with CNS melanomas who had neurocutaneous melanocytosis.<Reference refidx="9"/> All patients died 0.3 to 0.8 years after they were diagnosed.</Para></ListItem><ListItem>Family history of melanoma. </ListItem></ItemizedList><Para id="_1317">Phenotypic traits associated with an increased risk of melanoma in adults have been documented in children and adolescents with melanoma and include the following:<Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/><Reference refidx="15"/><Reference refidx="16"/></Para><ItemizedList id="_1450" Style="bullet"><ListItem>Exposure to UV sunlight. Increased exposure to ambient UV radiation increases disease risk. </ListItem><ListItem>Red hair.</ListItem><ListItem>Blue eyes.</ListItem><ListItem>Poor tanning ability.</ListItem><ListItem>Freckling.</ListItem><ListItem>Dysplastic nevi.</ListItem><ListItem>Increased number of melanocytic nevi.</ListItem></ItemizedList><Para id="_2465">Germline pathogenic variants associated with an increased risk of melanoma in children include the following:</Para><ItemizedList id="_2466" Style="bullet"><ListItem><Strong><GeneName>MC1R</GeneName> gene.</Strong> A multinational consortium performed a retrospective review of germline pathogenic variants in the <GeneName>MC1R</GeneName> gene.<Reference refidx="17"/>  The investigators analyzed data from 233 young patients (aged ≤20 years), 932 adult patients (aged ≥35 years), and 932 healthy adult controls.  <GeneName>MC1R</GeneName> variants were more prevalent in childhood and adolescent patients with melanoma than in adult patients with melanoma. This finding was especially true for patients aged 18 years or younger.</ListItem><ListItem><Strong><GeneName>CDKN2A</GeneName> gene (<GeneName>p16</GeneName> gene).</Strong> Familial melanoma comprises 8% to 12% of melanoma cases. <GeneName>p16</GeneName> germline pathogenic variants have been described in up to 7% of families with two first-degree relatives with melanoma and in up to 80% of families having one member with multiple primary melanomas.<Reference refidx="18"/> In a  prospective study of 60 families who had more than three members with melanoma,<Reference refidx="19"/> one-half of the 60 families studied had a germline <GeneName>CDKN2A</GeneName> pathogenic variant. Regardless of <GeneName>CDKN2A</GeneName> status, melanoma-prone families were found to have sixfold to 28-fold higher percentages of members with pediatric melanoma compared with the general population of patients with melanoma in the United States. Within <GeneName>CDKN2A</GeneName>-positive families, pediatric patients with melanoma were significantly more likely to have multiple melanomas compared with their relatives who were older than 20 years at diagnosis (71% vs. 38%, respectively; <Emphasis>P</Emphasis> = .004). <GeneName>CDKN2A</GeneName>-positive families had significantly higher percentages of pediatric patients with melanoma compared with <GeneName>CDKN2A</GeneName>-negative families (11.1% vs. 2.5%, respectively; <Emphasis>P</Emphasis> = .004).</ListItem><ListItem><Strong><GeneName>MITF</GeneName> p.E318K variant.</Strong> In one series of patients younger than 21 years, 3 of 123 patients (2.4%) had an <GeneName>MITF</GeneName> substitution considered to confer a moderate risk of developing cutaneous melanoma.<Reference refidx="20"/><Reference refidx="21"/></ListItem></ItemizedList><ReferenceSection><Citation idx="1" PMID="7845431" MedlineID="95147937">Ceballos PI, Ruiz-Maldonado R, Mihm MC: Melanoma in children. N Engl J Med 332 (10): 656-62, 1995.</Citation><Citation idx="2" PMID="14642927">Pappo AS: Melanoma in children and adolescents. Eur J Cancer 39 (18): 2651-61, 2003.</Citation><Citation idx="3" PMID="15800318">Kleinerman RA, Tucker MA, Tarone RE, et al.: Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 23 (10): 2272-9, 2005.</Citation><Citation idx="4" PMID="16361718">Shibuya H, Kato A, Kai N, et al.: A case of Werner syndrome with three primary lesions of malignant melanoma. J Dermatol 32 (9): 737-44, 2005.</Citation><Citation idx="5" PMID="22355046">Kleinerman RA, Yu CL, Little MP, et al.: Variation of second cancer risk by family history of retinoblastoma among long-term survivors. J Clin Oncol 30 (9): 950-7, 2012.</Citation><Citation idx="6" PMID="15787820">Hale EK, Stein J, Ben-Porat L, et al.: Association of melanoma and neurocutaneous melanocytosis with large congenital melanocytic naevi--results from the NYU-LCMN registry. Br J Dermatol 152 (3): 512-7, 2005.</Citation><Citation idx="7" PMID="15295923">Makkar HS, Frieden IJ: Neurocutaneous melanosis. Semin Cutan Med Surg 23 (2): 138-44, 2004.</Citation><Citation idx="8" PMID="28253523">Kinsler VA, O'Hare P, Jacques T, et al.: MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children. Br J Cancer 116 (8): 990-993, 2017.</Citation><Citation idx="9" PMID="38225622">Abele M, Forchhammer S, Eigentler TK, et al.: Melanoma of the central nervous system based on neurocutaneous melanocytosis in childhood: A rare but fatal condition. Pediatr Blood Cancer 71 (4): e30859, 2024.</Citation><Citation idx="10" PMID="9695084" MedlineID="98360197">Heffernan AE, O'Sullivan A: Pediatric sun exposure. Nurse Pract 23 (7): 67-8, 71-8, 83-6, 1998.</Citation><Citation idx="11" PMID="9080889" MedlineID="97235970">Berg P, Lindelöf B: Differences in malignant melanoma between children and adolescents. A 35-year epidemiological study. Arch Dermatol 133 (3): 295-7, 1997.</Citation><Citation idx="12" PMID="9335442" MedlineID="97474418">Elwood JM, Jopson J: Melanoma and sun exposure: an overview of published studies. Int J Cancer 73 (2): 198-203, 1997.</Citation><Citation idx="13" PMID="16034049">Strouse JJ, Fears TR, Tucker MA, et al.: Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. J Clin Oncol 23 (21): 4735-41, 2005.</Citation><Citation idx="14" PMID="8985086">Whiteman DC, Valery P, McWhirter W, et al.: Risk factors for childhood melanoma in Queensland, Australia. Int J Cancer 70 (1): 26-31, 1997.</Citation><Citation idx="15" PMID="12115352" MedlineID="22109426">Tucker MA, Fraser MC, Goldstein AM, et al.: A natural history of melanomas and dysplastic nevi: an atlas of lesions in melanoma-prone families. Cancer 94 (12): 3192-209, 2002.</Citation><Citation idx="16" PMID="19911673">Ducharme EE, Silverberg NB: Pediatric malignant melanoma: an update on epidemiology, detection, and prevention. Cutis 84 (4): 192-8, 2009.</Citation><Citation idx="17" PMID="30872112">Pellegrini C, Botta F, Massi D, et al.: MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort. Lancet Child Adolesc Health 3 (5): 332-342, 2019.</Citation><Citation idx="18" PMID="9425228">Soufir N, Avril MF, Chompret A, et al.: Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 7 (2): 209-16, 1998.</Citation><Citation idx="19" PMID="30207590">Goldstein AM, Stidd KC, Yang XR, et al.: Pediatric melanoma in melanoma-prone families. Cancer 124 (18): 3715-3723, 2018.</Citation><Citation idx="20" PMID="34664323">Pellegrini C, Raimondi S, Di Nardo L, et al.: Melanoma in children and adolescents: analysis of susceptibility genes in 123 Italian patients. J Eur Acad Dermatol Venereol 36 (2): 213-221, 2022.</Citation><Citation idx="21" PMID="33051548">Guhan SM, Artomov M, McCormick S, et al.: Cancer risks associated with the germline MITF(E318K) variant. Sci Rep 10 (1): 17051, 2020.</Citation></ReferenceSection></SummarySection><SummarySection id="_706"><Title>Diagnostic Evaluation</Title><Para id="_709">The diagnosis of pediatric melanomas may be difficult, and many of these lesions may be confused with so-called  melanocytic lesions with unknown malignant potential.<Reference refidx="1"/> These lesions are  biologically different from melanoma and benign nevi.<Reference refidx="1"/><Reference refidx="2"/> The terms Spitz nevus and spitzoid melanoma are also commonly used, creating additional confusion. One retrospective study found that children aged 10 years or older were more likely to present with amelanotic lesions, bleeding, uniform color, variable diameter, and elevation (such as a de novo bump).<Reference refidx="3"/>[<LOERef href="CDR0000810035" dictionary="NotSet" audience="Health professional">Level of evidence C1</LOERef>]  </Para><Para id="_1520">The diagnostic evaluation of pediatric melanomas includes the following:</Para><ItemizedList id="_1521" Style="bullet"><ListItem><Strong>Biopsy or excision. </Strong>Biopsy or excision is necessary to diagnose any skin cancer and determine additional treatment.  Although basal cell carcinomas and
squamous cell carcinomas are generally curable with surgery alone, melanoma requires greater consideration because of its potential
for metastasis.  The width of surgical margins in melanoma is dictated by the site, size, and thickness of the lesion and ranges from 0.5 cm for <Emphasis>in situ</Emphasis> lesions to 2 cm or more for thicker lesions.<Reference refidx="4"/>  To achieve negative margins in children, wide excision with
skin grafting may become necessary in selected cases. Partial shave biopsy may compromise microstaging and is associated with more invasive, definitive surgical treatments.<Reference refidx="5"/> </ListItem><ListItem><Strong>Lymph node evaluation.</Strong> Examination of regional lymph nodes using sentinel lymph node biopsy  has become routine in many centers.<Reference refidx="6"/><Reference refidx="7"/> Sentinel lymph node biopsy is recommended for patients with lesions measuring  0.8 cm or larger,<Reference refidx="4"/> as well as for patients whose lesions are less than 0.8 cm and who have ulceration or other unfavorable features such as lymphovascular invasion, high mitotic rate, young age, or a positive margin biopsy.<Reference refidx="4"/><Reference refidx="6"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/> <Para id="_2467">The indications for this procedure in patients with spitzoid melanomas have not been clearly defined. In a systematic review of 541 patients   with atypical Spitz tumors, 303 (56%) underwent sentinel lymph node biopsy and 119 (39%) had a positive sentinel node. Further lymph node dissection in 97 of these patients revealed additional positive nodes in 18 patients (19%).<Reference refidx="11"/> Despite the high incidence of nodal metastases, only six patients developed disseminated disease. This finding challenges the prognostic and therapeutic benefit of this procedure in children with these lesions. In the future, molecular markers, such as the presence of <GeneName>TERT</GeneName> promoter variants, may  help identify which patients might benefit from this procedure.<Reference refidx="12"/></Para><Para id="_1522">The role of complete lymph node dissection after a positive sentinel node and the value of adjuvant therapies in these patients is discussed in the <SummaryRef href="CDR0000800109#_710" url="/types/skin/hp/child-melanoma-treatment-pdq">Treatment of Childhood Melanoma</SummaryRef> section.</Para></ListItem><ListItem><Strong>Laboratory and imaging evaluation.</Strong> Patients who present with conventional or adult-type melanoma should undergo laboratory and imaging evaluations based on adult guidelines.  For more information, see the <SummaryRef href="CDR0000062917#_884" url="/types/skin/hp/melanoma-treatment-pdq">Stage Information for Melanoma</SummaryRef> section in Melanoma Treatment. In contrast, patients who are diagnosed with spitzoid melanomas have a low risk of recurrence and excellent clinical outcomes and do not require extensive radiographic evaluation either at diagnosis or follow-up.<Reference refidx="13"/></ListItem></ItemizedList><Para id="_2506">A Children's Oncology Group–led panel of experts from different specialties have developed recommendations for the diagnostic evaluation and surgical management of cutaneous melanomas, atypical Spitz tumors, and non-Spitz melanocytic tumors.<Reference refidx="14"/></Para><ReferenceSection><Citation idx="1" PMID="20403119">Berk DR, LaBuz E, Dadras SS, et al.: Melanoma and melanocytic tumors of uncertain malignant potential in children, adolescents and young adults--the Stanford experience 1995-2008. Pediatr Dermatol 27 (3): 244-54, 2010 May-Jun.</Citation><Citation idx="2" PMID="20118771">Cerroni L, Barnhill R, Elder D, et al.: Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008. Am J Surg Pathol 34 (3): 314-26, 2010.</Citation><Citation idx="3" PMID="23395590">Cordoro KM, Gupta D, Frieden IJ, et al.: Pediatric melanoma: results of a large cohort study and proposal for modified ABCD detection criteria for children. J Am Acad Dermatol 68 (6): 913-25, 2013.</Citation><Citation idx="4" PMID="34174159">Ferrari A, Lopez Almaraz R, Reguerre Y, et al.: Cutaneous melanoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. Pediatr Blood Cancer 68 (Suppl 4): e28992, 2021.</Citation><Citation idx="5" PMID="39235826">Arjunan A, Wardrop M, Malek MM, et al.: Treatment outcomes following partial shave biopsy of atypical and malignant melanocytic tumors in pediatric patients. Melanoma Res 34 (6): 544-548, 2024.</Citation><Citation idx="6" PMID="16912589">Shah NC, Gerstle JT, Stuart M, et al.: Use of sentinel lymph node biopsy and high-dose interferon in pediatric patients with high-risk melanoma: the Hospital for Sick Children experience. J Pediatr Hematol Oncol 28 (8): 496-500, 2006.</Citation><Citation idx="7" PMID="18697712">Kayton ML, La Quaglia MP: Sentinel node biopsy for melanocytic tumors in children. Semin Diagn Pathol 25 (2): 95-9, 2008.</Citation><Citation idx="8" PMID="33845460">Swetter SM, Thompson JA, Albertini MR, et al.: NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. J Natl Compr Canc Netw 19 (4): 364-376, 2021.</Citation><Citation idx="9" PMID="18697711">Ariyan CE, Coit DG: Clinical aspects of sentinel lymph node biopsy in melanoma. Semin Diagn Pathol 25 (2): 86-94, 2008.</Citation><Citation idx="10" PMID="14504508">Pacella SJ, Lowe L, Bradford C, et al.: The utility of sentinel lymph node biopsy in head and neck melanoma in the pediatric population. Plast Reconstr Surg 112 (5): 1257-65, 2003.</Citation><Citation idx="11" PMID="24694641">Lallas A, Kyrgidis A, Ferrara G, et al.: Atypical Spitz tumours and sentinel lymph node biopsy: a systematic review. Lancet Oncol 15 (4): e178-83, 2014.</Citation><Citation idx="12" PMID="26061100">Lee S, Barnhill RL, Dummer R, et al.: TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. Sci Rep 5: 11200, 2015.</Citation><Citation idx="13" PMID="30124237">Halalsheh H, Kaste SC, Navid F, et al.: The role of routine imaging in pediatric cutaneous melanoma. Pediatr Blood Cancer 65 (12): e27412, 2018.</Citation><Citation idx="14" PMID="39365959">Sargen MR, Barnhill RL, Elder DE, et al.: Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group. J Clin Oncol 43 (9): 1157-1167, 2025.</Citation></ReferenceSection></SummarySection><SummarySection id="_1453"><Title>Molecular Features</Title><Para id="_2468">Accurate diagnosis of pediatric melanocytic lesions is essential for optimal risk stratification and treatment planning. </Para><Para id="_7">Melanoma-related conditions with malignant potential that arise in the pediatric population can be classified into the following three general groups:<Reference refidx="1"/></Para><ItemizedList id="_844" Style="bullet"><ListItem>Spitzoid melanocytic tumors ranging from atypical Spitz tumors to spitzoid melanomas.</ListItem><ListItem>Melanoma arising in older adolescents that shares characteristics with adult melanoma (i.e., conventional melanoma). </ListItem><ListItem>Large/giant congenital melanocytic nevus.</ListItem></ItemizedList><Para id="_2469">Lesions categorized as Spitz lesions are challenging to diagnose. Morphological assessment alone has significant limitations, and there is low interobserver expert agreement.<Reference refidx="2"/></Para><Para id="_845">Genomic alterations involving multiple genes have been reported in melanocytic lesions. The characteristics of each tumor are summarized in <SummaryRef href="CDR0000800109#_843" url="/types/skin/hp/child-melanoma-treatment-pdq">Table 1</SummaryRef>.</Para><ItemizedList id="_2479" Style="bullet"><ListItem>The genomic landscape of spitzoid melanomas is characterized by kinase gene fusions involving various genes, including <GeneName>RET</GeneName>, <GeneName>MAP3K8</GeneName>, <GeneName>ROS1</GeneName>, <GeneName>NTRK1</GeneName>, <GeneName>ALK</GeneName>, <GeneName>MET</GeneName>, and <GeneName>BRAF</GeneName>.<Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/> These fusion genes have been reported in approximately 50% of cases and occur in a mutually exclusive manner.<Reference refidx="1"/><Reference refidx="4"/></ListItem><ListItem>In a retrospective analysis of spitzoid tumors from 49 patients, whole-genome and transcriptome sequencing (RNA-Seq) found in-frame fusions or C-terminal truncations of <GeneName>MAP3K8</GeneName> in 33% of cases.<Reference refidx="6"/> </ListItem><ListItem><GeneName>TERT</GeneName> promoter variants are uncommon in spitzoid melanocytic lesions and were observed in only 4 of 56 patients evaluated in one series. However, each of the four cases with <GeneName>TERT</GeneName> promoter variants experienced hematogenous metastases and died. This finding supports the potential for <GeneName>TERT</GeneName> promoter variants to predict aggressive clinical behavior in children with spitzoid melanocytic neoplasms, but additional study is needed to define the role of wild-type <GeneName>TERT</GeneName> promoter status in predicting clinical behavior in patients with primary site spitzoid tumors.<Reference refidx="4"/></ListItem><ListItem>A retrospective analysis of 352 cases of Spitz nevi identified oncogenic drivers in 76% of the patients.<Reference refidx="7"/> No microscopic features allowed the reliable prediction of <GeneName>ROS1</GeneName> and <GeneName>NTRK1</GeneName> overexpressing cases. In contrast, a plexiform pattern was associated with <GeneName>ALK</GeneName> overexpression. The pseudo-schwannoma variant was highly suggestive of <GeneName>NTRK3</GeneName>-rearranged cases. Atypical/malignant tumor, severe cellular atypia, and p16 loss were associated with <GeneName>MAP3K8</GeneName> rearrangements. Sheet-like architecture and marked fibrosis of the stroma were associated with <GeneName>BRAF</GeneName> fusions.</ListItem></ItemizedList><Para id="_2394">In another study, 128 lesions were classified as Spitz tumors based on morphology (80 Spitz tumors, 26 Spitz melanomas, 22 melanomas with Spitz features).<Reference refidx="8"/></Para><ItemizedList id="_2470" Style="bullet"><ListItem> Kinase fusions or truncations were present in 81% of Spitz tumor cases and in 77% of Spitz melanoma cases. By comparison, 84% of melanomas with Spitz features had <GeneName>BRAF</GeneName>, <GeneName>NRAS</GeneName>, or <GeneName>NF1</GeneName> variants, and 61% of these had <GeneName>TERT</GeneName> promoter variants.</ListItem><ListItem> Among patients in the Spitz tumor group whose melanoma recurred, one patient  diagnosed with a <GeneName>BRAF</GeneName> V600E variant and a <GeneName>TERT</GeneName> promoter variant developed a distant recurrence and died. A second patient with a <GeneName>MAP3K8</GeneName> fusion had a local recurrence. </ListItem><ListItem>Two patients with Spitz melanoma had recurrences and both had <GeneName>BRAF</GeneName> V600E variants. </ListItem><ListItem>Of the three patients in the melanoma with spitzoid features group who had a recurrence, all had either a <GeneName>BRAF</GeneName> or <GeneName>NRAS</GeneName> variant with a concomitant <GeneName>TERT</GeneName> promoter variant.</ListItem><ListItem> After reclassifying these patients by their clinical and genomic characteristics, and by incorporating the <GeneName>BRAF</GeneName> or <GeneName>NRAS</GeneName> variants into the melanoma with Spitz features category, a significant difference in recurrence-free survival rates could be detected among the groups with Spitz tumors. This finding suggests that incorporation of genomic features can greatly improve the classification of these lesions.</ListItem></ItemizedList><Para id="_846"><Strong>Conventional melanoma.</Strong> The genomic landscape of conventional melanoma in children is represented by many of the genomic alterations that are found in adults with melanoma.<Reference refidx="1"/> A report from the Pediatric Cancer Genome Project observed that 15 cases of conventional melanoma had high burdens of somatic single-nucleotide variants (SNV), <GeneName>TERT</GeneName> promoter variants (12 of 13), and activating <GeneName>BRAF</GeneName> V600 variants (13 of 15). The melanoma cases also had variant spectrum signatures consistent with UV light damage. In addition, two-thirds of the cases had <GeneName>MC1R</GeneName> variants associated with an increased susceptibility to melanoma. An Australian study compared the whole-genome sequencing of melanomas in adolescents and young adults (age range, 15–30 years) with the sequencing of melanomas in older adults.<Reference refidx="9"/>  The frequencies of somatic variants in <GeneName>BRAF</GeneName> (96%) and <GeneName>PTEN</GeneName> (36%) in the adolescent and young adult cohort were double the rates observed in the adult cohort.  Adolescent and young adult melanomas contained a higher proportion of variant signatures unrelated to UV radiation than did mature adult melanomas, as a proportion of total variant burden.</Para><Para id="_848"><Strong>Large congenital melanocytic nevi.</Strong> Large congenital melanocytic nevi are reported to have activating <GeneName>NRAS</GeneName> Q61 variants with no other recurring variants noted.<Reference refidx="10"/>  Somatic mosaicism for <GeneName>NRAS</GeneName> Q61 variants has also been reported in patients with multiple congenital melanocytic nevi and neurocutaneous melanosis.<Reference refidx="11"/></Para><Para id="_2393">Integrating genomic analysis in the evaluation of pediatric melanocytic lesions can optimize diagnostic accuracy and provide important prognostic information for the treating physician. In a prospective registry of 70 patients with pediatric melanocytic lesions, the use of an integrated clinicopathological and genomic assessment optimized the pathological diagnosis and improved the ability to predict clinical outcomes in these patients.<Reference refidx="12"/></Para><OrderedList id="_2471" Style="LAlpha"><ListItem>Atypical Spitz tumor/Spitz melanoma.<ItemizedList id="_2472" Style="bullet"><ListItem> Patients with atypical Spitz tumors/Spitz melanomas were younger and had tumors predominantly located in the extremities. </ListItem><ListItem>Genomic lesions in these patients were characterized by kinase fusions most often involving <GeneName>MAP3K8</GeneName> and <GeneName>ALK</GeneName>.</ListItem><ListItem> Even though 62% of patients who had nodes sampled had nodal disease, none developed distant metastases and two developed locoregional recurrences.</ListItem><ListItem> Of the 33 patients tested, none of them had <GeneName>TERT</GeneName> promoter variants. However, <GeneName>CDKN2A</GeneName> was deleted in 15 patients. These findings  suggest that <GeneName>TERT</GeneName> promoter variants might be better predictors of aggressive clinical behavior (development of metastases) in these lesions.</ListItem></ItemizedList></ListItem><ListItem>Conventional melanoma.<ItemizedList id="_2473" Style="bullet"><ListItem> Patients with conventional melanoma (n = 17) were older and their tumors were more commonly located on the scalp or trunk.</ListItem><ListItem> Seven of 12 patients had a positive sentinel node.</ListItem><ListItem>Eleven of 17 patients had <GeneName>BRAF</GeneName> V600E variants.</ListItem><ListItem> Seven of 16 patients had <GeneName>TERT</GeneName> promoter variants, and three of these patients died.</ListItem></ItemizedList></ListItem><ListItem>Giant nevi.<ItemizedList id="_2474" Style="bullet"><ListItem> Of the four patients with melanoma arising in a giant nevi, all had <GeneName>NRAS</GeneName> Q61 variants and all died of their disease.</ListItem></ItemizedList></ListItem></OrderedList><Table id="_843"><Title>Table 1.  Characteristics of Melanocytic Lesions</Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="50.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="50.00%"/><THead><Row><entry>Tumor






</entry><entry>Affected Gene


 


</entry></Row></THead><TBody><Row><entry>Melanoma</entry><entry><GeneName>BRAF</GeneName>, <GeneName>NRAS</GeneName>, <GeneName>KIT, NF1</GeneName></entry></Row><Row><entry>Spitz melanoma</entry><entry>Kinase fusions (<GeneName>RET</GeneName>, <GeneName>ROS</GeneName>, <GeneName>MET</GeneName>, <GeneName>ALK</GeneName>, <GeneName>BRAF</GeneName>, <GeneName>MAP3K8</GeneName>, <GeneName>NTRK1</GeneName>); <GeneName>BAP1</GeneName> loss in the presence of <GeneName>BRAF</GeneName> variant</entry></Row><Row><entry>Spitz nevus</entry><entry><GeneName>HRAS</GeneName>; <GeneName>BRAF</GeneName> and <GeneName>NRAS</GeneName> (uncommon); kinase fusions (<GeneName>ROS</GeneName>, <GeneName>ALK</GeneName>, <GeneName>NTRK1</GeneName>, <GeneName>BRAF</GeneName>, <GeneName>RET</GeneName>, <GeneName>MAP3K8</GeneName>)</entry></Row><Row><entry>Acquired nevus</entry><entry><GeneName>BRAF</GeneName></entry></Row><Row><entry>Dysplastic nevus</entry><entry><GeneName>BRAF</GeneName>, <GeneName>NRAS</GeneName></entry></Row><Row><entry>Blue nevus</entry><entry><GeneName>GNAQ</GeneName></entry></Row><Row><entry>Ocular melanoma</entry><entry><GeneName>GNAQ</GeneName></entry></Row><Row><entry>Congenital nevi
</entry><entry>
<GeneName>NRAS
</GeneName></entry></Row></TBody></TGroup></Table><ReferenceSection><Citation idx="1" PMID="25268584">Lu C, Zhang J, Nagahawatte P, et al.: The genomic landscape of childhood and adolescent melanoma. J Invest Dermatol 135 (3): 816-23, 2015.</Citation><Citation idx="2" PMID="24618612">Gerami P, Busam K, Cochran A, et al.: Histomorphologic assessment and interobserver diagnostic reproducibility of atypical spitzoid melanocytic neoplasms with long-term follow-up. Am J Surg Pathol 38 (7): 934-40, 2014.</Citation><Citation idx="3" PMID="24445538">Wiesner T, He J, Yelensky R, et al.: Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun 5: 3116, 2014.</Citation><Citation idx="4" PMID="26061100">Lee S, Barnhill RL, Dummer R, et al.: TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. Sci Rep 5: 11200, 2015.</Citation><Citation idx="5" PMID="26013381">Yeh I, Botton T, Talevich E, et al.: Activating MET kinase rearrangements in melanoma and Spitz tumours. Nat Commun 6: 7174, 2015.</Citation><Citation idx="6" PMID="30833747">Newman S, Fan L, Pribnow A, et al.: Clinical genome sequencing uncovers potentially targetable truncations and fusions of MAP3K8 in spitzoid and other melanomas. Nat Med 25 (4): 597-602, 2019.</Citation><Citation idx="7" PMID="34761304">Kervarrec T, Pissaloux D, Tirode F, et al.: Morphologic features in a series of 352 Spitz melanocytic proliferations help predict their oncogenic drivers. Virchows Arch 480 (2): 369-382, 2022.</Citation><Citation idx="8" PMID="32004563">Quan VL, Zhang B, Zhang Y, et al.: Integrating Next-Generation Sequencing with Morphology Improves Prognostic and Biologic Classification of Spitz Neoplasms. J Invest Dermatol 140 (8): 1599-1608, 2020.</Citation><Citation idx="9" PMID="30178487">Wilmott JS, Johansson PA, Newell F, et al.: Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility. Int J Cancer 144 (5): 1049-1060, 2019.</Citation><Citation idx="10" PMID="24129063">Charbel C, Fontaine RH, Malouf GG, et al.: NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi. J Invest Dermatol 134 (4): 1067-74, 2014.</Citation><Citation idx="11" PMID="23392294">Kinsler VA, Thomas AC, Ishida M, et al.: Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. J Invest Dermatol 133 (9): 2229-36, 2013.</Citation><Citation idx="12" PMID="34228365">Pappo AS, McPherson V, Pan H, et al.: A prospective, comprehensive registry that integrates the molecular analysis of pediatric and adolescent melanocytic lesions. Cancer 127 (20): 3825-3831, 2021.</Citation></ReferenceSection></SummarySection><SummarySection id="_704"><Title>Prognosis and Prognostic Factors</Title><Para id="_2481">Children and adolescents with melanoma generally have a favorable outcome. <SummaryRef href="CDR0000800109#_2482" url="/types/skin/hp/child-melanoma-treatment-pdq">Table 2</SummaryRef> shows the  5-year survival rates for children and adolescents with melanoma in the United States by age for the years between 2013 and 2019.<Reference refidx="1"/></Para><Table id="_2482"><Title>Table 2. Survival Rates for Children and Adolescents With Melanoma in the United States Between 2013 and 2019<Superscript>a</Superscript></Title><TGroup Cols="4"><ColSpec ColName="col0" ColWidth="25.00%"/><ColSpec ColName="col1" ColWidth="25.00%"/><ColSpec ColName="col2" ColWidth="25.00%"/><ColSpec ColName="col3" ColWidth="25.00%"/><THead><Row><entry>Age (y)</entry><entry>5-Year Relative Survival Rate (%)</entry><entry>Lower 95% Confidence Interval</entry><entry>Upper 95% Confidence Interval</entry></Row></THead><TFoot><Row><entry NameEnd="col3" NameSt="col0"><Superscript>a</Superscript>Adapted from the National Childhood Cancer Registry. NCCR*Explorer: An interactive website for NCCR cancer statistics [Internet]. National Cancer Institute; 2023 Sep 7. [updated: 2023 Sep 8; cited 2024 Aug 12]. Available from: https://nccrexplorer.ccdi.cancer.gov.</entry></Row></TFoot><TBody><Row><entry>Age &lt;1</entry><entry>85</entry><entry>63</entry><entry>94</entry></Row><Row><entry>Ages 1–4</entry><entry>83</entry><entry>71</entry><entry>90</entry></Row><Row><entry>Ages 5–9</entry><entry>99</entry><entry>95</entry><entry>100</entry></Row><Row><entry>Ages 10–14</entry><entry>95</entry><entry>90</entry><entry>97</entry></Row><Row><entry>Ages 15–19</entry><entry>97</entry><entry>95</entry><entry>99</entry></Row></TBody></TGroup></Table><Para id="_735">Pediatric melanoma shares many similarities with adult melanoma, and the prognosis depends on disease stage.<Reference refidx="2"/> As in adults, most pediatric patients (about 75%) have localized disease and excellent outcomes.<Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/></Para><Para id="_1146">The outcome for patients with nodal disease is intermediate, with about 60% expected to survive long term.<Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/> In one study, the outcome for patients with metastatic disease was favorable,<Reference refidx="4"/> but this result was not duplicated in another study from the National Cancer Database.<Reference refidx="6"/></Para><Para id="_705">Children younger than 10 years who have melanoma often present with the following:<Reference refidx="2"/><Reference refidx="4"/><Reference refidx="6"/><Reference refidx="7"/></Para><ItemizedList id="_2478" Style="bullet"><ListItem> Poor prognostic features.</ListItem><ListItem>Non-White races. </ListItem><ListItem>Head and neck primary tumors.</ListItem><ListItem>Thicker primary lesions.</ListItem><ListItem>Higher incidence of spitzoid morphology vascular invasion and nodal metastases.</ListItem><ListItem>Syndromes that predispose them to melanoma.</ListItem></ItemizedList><Para id="_1148">The use of sentinel lymph node biopsy for staging pediatric melanoma has become widespread. Primary tumor thickness and ulceration have been correlated with a higher incidence of nodal involvement.<Reference refidx="8"/> Studies addressing nodal involvement  and the lack of effect on outcome have reported the following findings:</Para><ItemizedList id="_2057" Style="bullet"><ListItem>Younger patients appear to have a higher incidence of nodal involvement, but  this finding does not appear to significantly impact clinical outcomes.<Reference refidx="7"/><Reference refidx="9"/></ListItem><ListItem>In other series of pediatric melanoma, a higher incidence of nodal involvement did not appear to impact survival.<Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/></ListItem><ListItem>In a retrospective cohort study from the National Cancer Database, all records of patients with an index diagnosis of melanoma from 1998 to 2011 were reviewed. The data were abstracted from medical records, operative reports, and pathology reports and did not undergo central review.  A total of 350,928 patients with adequate information were identified; 306 patients were aged 1 to 10 years  (pediatric), and 3,659 patients were aged 11 to 20 years (adolescent).<Reference refidx="13"/><ItemizedList id="_2475" Style="bullet"><ListItem> Pediatric patients had longer overall survival (OS) than adolescent patients (hazard ratio [HR], 0.50; 95% confidence interval [CI], 0.25–0.98) and patients older than 20 years (HR, 0.11; 95% CI, 0.06–0.21).</ListItem><ListItem> Adolescents had longer OS than adults.</ListItem><ListItem> No difference in OS was found between pediatric node-positive patients and node-negative patients.</ListItem><ListItem> In pediatric patients, sentinel lymph node biopsy and completion of lymph node dissection were not associated with increased OS.</ListItem><ListItem> In adolescents, nodal positivity was a significant negative prognostic indicator (HR, 4.82; 95% CI, 3.38–6.87).</ListItem></ItemizedList></ListItem></ItemizedList><Para id="_1451">The association of lesion thickness with clinical outcome is controversial in pediatric melanoma.<Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="14"/><Reference refidx="15"/><Reference refidx="16"/><Reference refidx="17"/><Reference refidx="18"/> In addition, it is unclear why some variables that correlate with survival in adults are not replicated in children. One possible explanation for this difference might be the inclusion of patients who have lesions that are not true melanomas in the adult series, considering the problematic histological distinction between true melanoma and melanocytic lesions with unknown malignant potential. These patients are not included in pediatric trials.<Reference refidx="19"/><Reference refidx="20"/></Para><ReferenceSection><Citation idx="1">National Cancer Institute: NCCR*Explorer: An interactive website for NCCR cancer statistics. Bethesda, MD: National Cancer Institute. <ExternalRef xref="https://NCCRExplorer.ccdi.cancer.gov/">Available online</ExternalRef>. Last accessed February 25, 2025.</Citation><Citation idx="2" PMID="20549825">Paradela S, Fonseca E, Pita-Fernández S, et al.: Prognostic factors for melanoma in children and adolescents: a clinicopathologic, single-center study of 137 Patients. Cancer 116 (18): 4334-44, 2010.</Citation><Citation idx="3" PMID="23589817">Wong JR, Harris JK, Rodriguez-Galindo C, et al.: Incidence of childhood and adolescent melanoma in the United States: 1973-2009. Pediatrics 131 (5): 846-54, 2013.</Citation><Citation idx="4" PMID="16034049">Strouse JJ, Fears TR, Tucker MA, et al.: Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. J Clin Oncol 23 (21): 4735-41, 2005.</Citation><Citation idx="5" PMID="25794606">Brecht IB, Garbe C, Gefeller O, et al.: 443 paediatric cases of malignant melanoma registered with the German Central Malignant Melanoma Registry between 1983 and 2011. Eur J Cancer 51 (7): 861-8, 2015.</Citation><Citation idx="6" PMID="17416855">Lange JR, Palis BE, Chang DC, et al.: Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. J Clin Oncol 25 (11): 1363-8, 2007.</Citation><Citation idx="7" PMID="21451389">Moore-Olufemi S, Herzog C, Warneke C, et al.: Outcomes in pediatric melanoma: comparing prepubertal to adolescent pediatric patients. Ann Surg 253 (6): 1211-5, 2011.</Citation><Citation idx="8" PMID="22565612">Mu E, Lange JR, Strouse JJ: Comparison of the use and results of sentinel lymph node biopsy in children and young adults with melanoma. Cancer 118 (10): 2700-7, 2012.</Citation><Citation idx="9" PMID="23838920">Balch CM, Soong SJ, Gershenwald JE, et al.: Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol 20 (12): 3961-8, 2013.</Citation><Citation idx="10" PMID="11037854" MedlineID="20489554">Gibbs P, Moore A, Robinson W, et al.: Pediatric melanoma: are recent advances in the management of adult melanoma relevant to the pediatric population. J Pediatr Hematol Oncol 22 (5): 428-32, 2000 Sep-Oct.</Citation><Citation idx="11" PMID="17577228">Livestro DP, Kaine EM, Michaelson JS, et al.: Melanoma in the young: differences and similarities with adult melanoma: a case-matched controlled analysis. Cancer 110 (3): 614-24, 2007.</Citation><Citation idx="12" PMID="22864798">Han D, Zager JS, Han G, et al.: The unique clinical characteristics of melanoma diagnosed in children. Ann Surg Oncol 19 (12): 3888-95, 2012.</Citation><Citation idx="13" PMID="27364504">Lorimer PD, White RL, Walsh K, et al.: Pediatric and Adolescent Melanoma: A National Cancer Data Base Update. Ann Surg Oncol 23 (12): 4058-4066, 2016.</Citation><Citation idx="14" PMID="2303989">Rao BN, Hayes FA, Pratt CB, et al.: Malignant melanoma in children: its management and prognosis. J Pediatr Surg 25 (2): 198-203, 1990.</Citation><Citation idx="15" PMID="19635298">Aldrink JH, Selim MA, Diesen DL, et al.: Pediatric melanoma: a single-institution experience of 150 patients. J Pediatr Surg 44 (8): 1514-21, 2009.</Citation><Citation idx="16" PMID="21075477">Tcheung WJ, Marcello JE, Puri PK, et al.: Evaluation of 39 cases of pediatric cutaneous head and neck melanoma. J Am Acad Dermatol 65 (2): e37-42, 2011.</Citation><Citation idx="17" PMID="24252782">Ferrari A, Bisogno G, Cecchetto G, et al.: Cutaneous melanoma in children and adolescents: the Italian rare tumors in pediatric age project experience. J Pediatr 164 (2): 376-82.e1-2, 2014.</Citation><Citation idx="18" PMID="25819019">Stanelle EJ, Busam KJ, Rich BS, et al.: Early-stage non-Spitzoid cutaneous melanoma in patients younger than 22 years of age at diagnosis: long-term follow-up and survival analysis. J Pediatr Surg 50 (6): 1019-23, 2015.</Citation><Citation idx="19" PMID="11756768">Lohmann CM, Coit DG, Brady MS, et al.: Sentinel lymph node biopsy in patients with diagnostically controversial spitzoid melanocytic tumors. Am J Surg Pathol 26 (1): 47-55, 2002.</Citation><Citation idx="20" PMID="12518375">Su LD, Fullen DR, Sondak VK, et al.: Sentinel lymph node biopsy for patients with problematic spitzoid melanocytic lesions: a report on 18 patients. Cancer 97 (2): 499-507, 2003.</Citation></ReferenceSection></SummarySection><SummarySection id="_1864"><SectMetaData><SectionType>Unusual Cancers Special Considerations</SectionType></SectMetaData><Title>Special Considerations for the Treatment of Children With Cancer</Title>

<Para id="_1864_md_3">Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.<Reference refidx="1"/>    Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence.  This multidisciplinary team approach incorporates the skills
of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation
to achieve optimal survival and quality of life:</Para>
        <ItemizedList id="_1864_md_4" Style="bullet"><ListItem>Primary care physicians.</ListItem><ListItem>Pediatric surgeons.</ListItem><ListItem>Pathologists.</ListItem><ListItem>Pediatric radiation
oncologists.</ListItem><ListItem>Pediatric medical oncologists and hematologists.</ListItem><ListItem>Ophthalmologists.</ListItem><ListItem> Rehabilitation
specialists.</ListItem><ListItem>Pediatric oncology nurses.</ListItem><ListItem>Social workers.</ListItem><ListItem>Child-life professionals.</ListItem><ListItem>Psychologists.</ListItem><ListItem>Nutritionists.</ListItem></ItemizedList>
 <Para id="_1864_md_5">For specific information about supportive care for children and adolescents with cancer, see the summaries on <ExternalRef xref="https://www.cancer.gov/publications/pdq/information-summaries/supportive-care">Supportive and Palliative Care</ExternalRef>.</Para><Para id="_1864_md_6">The American Academy of Pediatrics has outlined guidelines for
pediatric cancer centers and their role in the treatment of children and adolescents
with cancer.<Reference refidx="2"/>  At
these centers, clinical trials are available for most  types of cancer that occur in children and adolescents, and the opportunity
to participate is offered to most patients and their families.  Clinical
trials for children and adolescents diagnosed with cancer are generally
designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis.  Most of the progress in identifying curative
therapies for childhood cancers has been achieved through clinical trials. 
Information about ongoing clinical trials is available from the <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">NCI website</ExternalRef>.</Para><Para id="_1864_md_7">Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.<Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/>  Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment.  For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see <SummaryRef href="CDR0000343584" url="/types/childhood-cancers/late-effects-hp-pdq">Late Effects of Treatment for Childhood Cancer</SummaryRef>.</Para>
<Para id="_1864_md_8">Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.<Reference refidx="6"/> The U.S. <ExternalRef xref="https://www.congress.gov/107/plaws/publ280/PLAW-107publ280.pdf">Rare Diseases Act of 2002</ExternalRef> defines a rare disease as one that affects populations smaller than 200,000 people in the United States. Therefore, all pediatric cancers are considered rare.</Para><Para id="_1864_md_9">The designation of a rare tumor is not uniform among pediatric and adult groups. In adults, rare cancers are defined as those with an annual incidence of fewer than six cases per 100,000 people. They account for up to 24% of all cancers diagnosed in the European Union and about 20% of all cancers diagnosed in the United States.<Reference refidx="7"/><Reference refidx="8"/> In children and adolescents, the designation of a rare tumor is not uniform among international groups, as follows:</Para><ItemizedList id="_1864_md_10" Style="bullet"><ListItem>A consensus effort between the European Union Joint Action on Rare Cancers and the European Cooperative Study Group for Rare Pediatric Cancers estimated that 11% of all cancers in patients younger than 20 years could be categorized as very rare. This consensus group defined very rare cancers as those with annual incidences of fewer than two cases per 1 million people. However, three additional histologies (thyroid carcinoma, melanoma, and testicular cancer) with incidences of more than two cases per 1 million people were also included  in the very rare group due to a lack of knowledge and expertise in the management of these tumors.<Reference refidx="9"/></ListItem><ListItem>The Children's Oncology Group defines rare pediatric cancers as those listed in the International Classification of Childhood Cancer subgroup XI, which includes thyroid cancers, melanomas and nonmelanoma skin cancers, and multiple types of carcinomas (e.g., adrenocortical carcinomas, nasopharyngeal carcinomas, and most adult-type carcinomas such as breast cancers and colorectal cancers).<Reference refidx="10"/>  These diagnoses account for about 5% of the cancers diagnosed in children aged 0 to 14 years and about 27% of the cancers diagnosed in adolescents aged 15 to 19 years.<Reference refidx="4"/><Para id="_11"> Most cancers in subgroup XI are either melanomas or thyroid cancers, with other cancer types accounting for only 2% of the cancers diagnosed in children aged 0 to 14 years and 9.3% of the cancers diagnosed in adolescents aged 15 to 19 years.</Para></ListItem></ItemizedList><Para id="_1864_md_12">These rare cancers are extremely challenging to study because of the relatively few patients with any individual diagnosis, the predominance of rare cancers in the adolescent population, and the small number of clinical trials for adolescents with rare cancers.</Para><Para id="_1837">Information about these tumors may also be found in sources relevant to
adults with cancer, such as <SummaryRef href="CDR0000062917" url="/types/skin/hp/melanoma-treatment-pdq">Melanoma Treatment</SummaryRef>.</Para><ReferenceSection><Citation idx="1" PMID="20404250">Smith MA, Seibel NL, Altekruse SF, et al.: Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28 (15): 2625-34, 2010.</Citation><Citation idx="2">American Academy of Pediatrics: Standards for pediatric cancer centers. Pediatrics  134 (2): 410-4, 2014. <ExternalRef xref="https://pediatrics.aappublications.org/content/134/2/410">Also available online</ExternalRef>. Last accessed February 25, 2025.</Citation><Citation idx="3" PMID="24853691">Smith MA, Altekruse SF, Adamson PC, et al.: Declining childhood and adolescent cancer mortality. Cancer 120 (16): 2497-506, 2014.</Citation><Citation idx="4">National Cancer Institute: NCCR*Explorer: An interactive website for NCCR cancer statistics. Bethesda, MD: National Cancer Institute. <ExternalRef xref="https://NCCRExplorer.ccdi.cancer.gov/">Available online</ExternalRef>. Last accessed February 25, 2025.</Citation><Citation idx="5">Surveillance Research Program, National Cancer Institute: SEER*Explorer: An interactive website for SEER cancer statistics. 	Bethesda, MD: National Cancer Institute. <ExternalRef xref="https://seer.cancer.gov/statistics-network/explorer/">Available online</ExternalRef>. Last accessed December 30, 2024.</Citation><Citation idx="6" PMID="24488779">Ward E, DeSantis C, Robbins A, et al.: Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 64 (2): 83-103, 2014 Mar-Apr.</Citation><Citation idx="7" PMID="28687376">Gatta G, Capocaccia R, Botta L, et al.: Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol 18 (8): 1022-1039, 2017.</Citation><Citation idx="8" PMID="28542893">DeSantis CE, Kramer JL, Jemal A: The burden of rare cancers in the United States. CA Cancer J Clin 67 (4): 261-272, 2017.</Citation><Citation idx="9" PMID="30785015">Ferrari A, Brecht IB, Gatta G, et al.: Defining and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare Cancers in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors. Eur J Cancer 110: 120-126, 2019.</Citation><Citation idx="10" PMID="20956621">Pappo AS, Krailo M, Chen Z, et al.: Infrequent tumor initiative of the Children's Oncology Group: initial lessons learned and their impact on future plans. J Clin Oncol 28 (33): 5011-6, 2010.</Citation></ReferenceSection></SummarySection><SummarySection id="_710"><Title>Treatment of Childhood Melanoma</Title><Para id="_2391">The European Cooperative Study Group for Pediatric Rare Tumors within the PARTNER project (Paediatric Rare Tumours Network - European Registry) has published recommendations for the diagnosis and treatment of children and adolescents with cutaneous melanoma. Some of these recommendations have been incorporated and summarized in the sections below.<Reference refidx="1"/> A Children's Oncology Group–led panel of experts from different specialties have also developed recommendations for the diagnostic evaluation and surgical management of cutaneous melanomas, atypical Spitz tumors, and non-Spitz melanocytic tumors.<Reference refidx="2"/></Para><Para id="_2273">Treatment options for childhood melanoma include the following:</Para><OrderedList id="_2326" Style="Arabic"><ListItem><SummaryRef href="CDR0000800109#_2275" url="/types/skin/hp/child-melanoma-treatment-pdq">Surgery</SummaryRef> and, in certain cases, sentinel lymph node biopsy and lymph node dissection.</ListItem><ListItem><SummaryRef href="CDR0000800109#_2327" url="/types/skin/hp/child-melanoma-treatment-pdq">Immune checkpoint inhibitors or BRAF/MEK inhibitors</SummaryRef>.</ListItem></OrderedList><SummarySection id="_2275"><Title>Surgery</Title><Para id="_2276">Surgery is the treatment of choice for patients with localized melanoma. Current guidelines recommend margins of resection as follows:</Para><ItemizedList id="_2277" Style="bullet"><ListItem>0.5 cm for melanoma <Emphasis>in situ</Emphasis>.</ListItem><ListItem>1 cm for melanoma thickness of less than 1 mm.</ListItem><ListItem>1 cm to 2 cm for melanoma thickness of 1.01 mm to 2 mm.</ListItem><ListItem>2 cm for tumor thickness of greater than 2 mm.</ListItem></ItemizedList><Para id="_2278">Sentinel lymph node biopsy should be considered in patients with thin lesions (≤1 mm) and ulceration, mitotic rate greater than 1/mm<Superscript>2</Superscript>, young age, and lesions larger than 1 mm with or without adverse features. Younger patients have a higher incidence of sentinel lymph node positivity, and this feature may adversely affect clinical outcomes.<Reference refidx="3"/><Reference refidx="4"/></Para><Para id="_2279">If the sentinel lymph node is positive, the option to undergo a complete lymph node dissection should be discussed. One adult trial  included 1,934 patients with a positive sentinel node, identified by either immunohistochemistry or polymerase chain reaction. The patients were randomly assigned to undergo either complete lymph node dissection or observation. The 3-year melanoma-specific survival rate was similar in both groups (86%), whereas the disease-free survival (DFS) rate was slightly higher in the dissection group (68% vs. 63%; <Emphasis>P</Emphasis> = .05). This advantage in DFS was related to a decrease in the rate of nodal recurrences because there was no difference in the distant metastases–free survival rates. It remains unknown how these results will affect the future surgical management of children and adolescents with melanoma.<Reference refidx="5"/>  </Para></SummarySection><SummarySection id="_2327"><Title>Immune Checkpoint Inhibitors or BRAF/MEK Inhibitors</Title><Para id="_2280">Targeted therapies and immunotherapy that have been effective in adults with melanoma should be pursued in pediatric patients with conventional melanoma and metastatic, recurrent, or progressive disease.</Para><Para id="_2281">Evidence (targeted therapy and immunotherapy):</Para><OrderedList id="_2282" Style="Arabic"><ListItem> A phase I trial of ipilimumab in children and adolescents, at a dose of  5 mg/kg or 10 mg/kg  every 3 weeks for four cycles,  enrolled 12 patients with melanoma.<Reference refidx="6"/><ItemizedList id="_2329" Style="bullet"><ListItem>One patient had prolonged stable disease.</ListItem><ListItem>This treatment demonstrated a similar toxicity profile as that seen in adults.</ListItem></ItemizedList></ListItem><ListItem>A phase II study of ipilimumab for adolescents with melanoma failed to achieve accrual goals and was closed. However, there was reported activity in patients with melanoma who were aged 12 to 17 years, with a similar safety profile as that seen in adults.<Reference refidx="7"/>[<LOERef href="CDR0000810033" dictionary="NotSet" audience="Health professional">Level of evidence B4</LOERef>]  <ItemizedList id="_2317" Style="bullet"><ListItem>At 1 year, three of four patients who received 3 mg/kg and five of eight patients who received 10 mg/kg were alive.</ListItem><ListItem>Two patients who received 10 mg/kg had partial responses, and one patient who received 3 mg/kg had stable disease.</ListItem><ListItem>In adults  with completely resected stage III cutaneous melanoma, prolonged DFS and overall survival have been seen with ipilimumab given at a dose of 10 mg/kg every 3 weeks for four doses, followed by one dose every 3 months for up to 3 years. This regimen caused little impairment in health-related quality of life.</ListItem></ItemizedList> </ListItem><ListItem>In a phase I/II trial of nivolumab for children and young adults with relapsed or refractory solid tumors or lymphoma, patients were treated with a dose of 3 mg/kg every 14 days.<Reference refidx="8"/><ItemizedList id="_2397" Style="bullet"><ListItem>The one patient with melanoma did not respond to therapy.</ListItem></ItemizedList></ListItem><ListItem>An open-label, single-arm, phase I/II trial of pembrolizumab for pediatric patients with advanced melanoma or programmed death-ligand 1 (PD-L1)–positive, advanced, relapsed, or refractory solid tumors or lymphoma reported the following:<Reference refidx="9"/><ItemizedList id="_2398" Style="bullet"><ListItem>Eight patients with melanoma were enrolled, and no responses were observed in these patients.</ListItem><ListItem>Five of these patients were PD-L1 negative.</ListItem></ItemizedList> </ListItem><ListItem>The Children's Oncology Group conducted a phase I/II trial of ipilimumab and nivolumab in 55 children and young adults with refractory or recurrent solid tumors.<Reference refidx="10"/><ItemizedList id="_2504" Style="bullet"><ListItem>The study identified a recommended phase II dose of 3 mg/kg for nivolumab and 1 mg/kg for ipilimumab. </ListItem><ListItem>No patients with melanoma were enrolled in the trial. However, partial responses were seen in one patient with rhabdomyosarcoma and one patient with Ewing sarcoma.</ListItem></ItemizedList></ListItem><ListItem>A retrospective review identified 99 patients with melanoma (aged 18 years or younger) who were treated with systemic therapy at 15 Italian academic centers. Eighty-one patients received anti–PD-1 therapy. The median age was 14 years (range, 2–18 years), and 37 patients were aged 12 years or younger. Thirty-eight patients received anti–PD-1 therapy in the adjuvant setting.<Reference refidx="11"/><ItemizedList id="_2505" Style="bullet"><ListItem>Of the patients who received adjuvant anti–PD-1 therapy, the  3-year progression-free survival rate was 70.6%, and the overall survival (OS) rate was 81.1%. </ListItem><ListItem>Of the 56 patients who received systemic therapy for advanced disease, 43 received first-line anti–PD-1–based therapy, while 12 patients received a second line, and 5 patients received a third line. Among patients who received first-line therapy with anti–PD-1 monotherapy, the objective response rate was 25%, and the 3-year OS rate was 34%. </ListItem><ListItem>Toxicities were consistent with previous studies that included adult patients with melanoma.</ListItem></ItemizedList></ListItem><ListItem>Dabrafenib and trametinib have been studied in two trials for pediatric patients with <GeneName>BRAF</GeneName> V600-altered low-grade gliomas. The U.S. Food and Drug Administration (FDA) approved this combination for this indication.<Reference refidx="12"/><Reference refidx="13"/> The FDA has also approved this combination for the treatment of patients with melanoma. </ListItem></OrderedList><Para id="_2501">No trials have been conducted specifically for the treatment of pediatric patients with melanoma. However, the FDA has approved the following immune and targeted therapies for pediatric and adolescent patients with melanoma based on studies of adult populations with or without pediatric participants:</Para><ItemizedList id="_2502" Style="bullet"><ListItem>Based on the positive results of two randomized clinical trials, the FDA approved adjuvant pembrolizumab for the treatment of patients aged 12 years and older with resected stage IIb, IIc, and III melanoma.<Reference refidx="14"/><Reference refidx="15"/></ListItem><ListItem>Based on the positive results of two randomized clinical trials, the FDA approved adjuvant nivolumab for the treatment of patients aged 12 years and older with resected stage IIb to IV melanoma.<Reference refidx="16"/><Reference refidx="17"/></ListItem><ListItem>Based on the positive results of one adult randomized clinical trial, the FDA approved nivolumab and ipilimumab for the treatment of children aged 12 years and older with unresectable or metastatic melanoma.<Reference refidx="18"/></ListItem><ListItem>Based on the positive results of one randomized clinical trial, the FDA approved nivolumab with relatlimab for the treatment of children aged 12 years and older with unresectable or metastatic melanoma.<Reference refidx="19"/></ListItem><ListItem>Although there have not been any prospective clinical trials using BRAF/MEK inhibitors in children and adolescents with melanoma, two adult studies have shown that the adjuvant combination of dabrafenib and trametinib results in a significantly lower risk of recurrence in patients with surgically resected stage III melanoma and in patients with previously untreated <GeneName>BRAF</GeneName> V600-altered metastatic melanoma.<Reference refidx="20"/><Reference refidx="21"/> The FDA granted accelerated approval to this drug combination for the treatment of patients with unresectable or metastatic melanoma who have <GeneName>BRAF</GeneName> V600E or V600K variants and for the adjuvant treatment of patients with melanoma who have <GeneName>BRAF</GeneName> V600E or V600K variants.</ListItem></ItemizedList><Para id="_2284">For more information, see <SummaryRef href="CDR0000062917" url="/types/skin/hp/melanoma-treatment-pdq">Melanoma Treatment</SummaryRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="34174159">Ferrari A, Lopez Almaraz R, Reguerre Y, et al.: Cutaneous melanoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. Pediatr Blood Cancer 68 (Suppl 4): e28992, 2021.</Citation><Citation idx="2" PMID="39365959">Sargen MR, Barnhill RL, Elder DE, et al.: Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group. J Clin Oncol 43 (9): 1157-1167, 2025.</Citation><Citation idx="3" PMID="22565612">Mu E, Lange JR, Strouse JJ: Comparison of the use and results of sentinel lymph node biopsy in children and young adults with melanoma. Cancer 118 (10): 2700-7, 2012.</Citation><Citation idx="4" PMID="22864798">Han D, Zager JS, Han G, et al.: The unique clinical characteristics of melanoma diagnosed in children. Ann Surg Oncol 19 (12): 3888-95, 2012.</Citation><Citation idx="5" PMID="27717298">Eggermont AM, Chiarion-Sileni V, Grob JJ, et al.: Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med 375 (19): 1845-1855, 2016.</Citation><Citation idx="6" PMID="26534966">Merchant MS, Wright M, Baird K, et al.: Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. Clin Cancer Res 22 (6): 1364-70, 2016.</Citation><Citation idx="7" PMID="29100190">Geoerger B, Bergeron C, Gore L, et al.: Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. Eur J Cancer 86: 358-363, 2017.</Citation><Citation idx="8" PMID="32192573">Davis KL, Fox E, Merchant MS, et al.: Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol 21 (4): 541-550, 2020.</Citation><Citation idx="9" PMID="31812554">Geoerger B, Kang HJ, Yalon-Oren M, et al.: Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol 21 (1): 121-133, 2020.</Citation><Citation idx="10" PMID="36190525">Davis KL, Fox E, Isikwei E, et al.: A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412. Clin Cancer Res 28 (23): 5088-5097, 2022.</Citation><Citation idx="11" PMID="39236557">Mandalà M, Ferrari A, Brecht IB, et al.: Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study). Eur J Cancer 211: 114305, 2024.</Citation><Citation idx="12" PMID="31811016">Hargrave DR, Bouffet E, Tabori U, et al.: Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study. Clin Cancer Res 25 (24): 7303-7311, 2019.</Citation><Citation idx="13" PMID="37733309">Bouffet E, Hansford JR, Garrè ML, et al.: Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations. N Engl J Med 389 (12): 1108-1120, 2023.</Citation><Citation idx="14" PMID="29658430">Eggermont AMM, Blank CU, Mandala M, et al.: Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med 378 (19): 1789-1801, 2018.</Citation><Citation idx="15" PMID="35367007">Luke JJ, Rutkowski P, Queirolo P, et al.: Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet 399 (10336): 1718-1729, 2022.</Citation><Citation idx="16" PMID="37845511">Kirkwood JM, Del Vecchio M, Weber J, et al.: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med 29 (11): 2835-2843, 2023.</Citation><Citation idx="17" PMID="28891423">Weber J, Mandala M, Del Vecchio M, et al.: Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med 377 (19): 1824-1835, 2017.</Citation><Citation idx="18" PMID="28889792">Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al.: Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 377 (14): 1345-1356, 2017.</Citation><Citation idx="19" PMID="34986285">Tawbi HA, Schadendorf D, Lipson EJ, et al.: Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med 386 (1): 24-34, 2022.</Citation><Citation idx="20" PMID="25399551">Robert C, Karaszewska B, Schachter J, et al.: Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372 (1): 30-9, 2015.</Citation><Citation idx="21" PMID="28891408">Long GV, Hauschild A, Santinami M, et al.: Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med 377 (19): 1813-1823, 2017.</Citation></ReferenceSection></SummarySection><SummarySection id="_1337"><Title>Treatment Options Under Clinical Evaluation for Childhood Melanoma</Title><Para id="_1995">Information about National Cancer Institute (NCI)–supported clinical trials can be found on the <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">NCI website</ExternalRef>. For information about clinical trials sponsored by other organizations, see the <ExternalRef xref="https://clinicaltrials.gov/">ClinicalTrials.gov website</ExternalRef>.</Para><Para id="_1996">The following is an example of a national and/or institutional clinical trial that is currently being conducted:</Para><ItemizedList id="_1339" Style="bullet"><ListItem><Strong><ProtocolRef nct_id="NCT02332668">NCT02332668</ProtocolRef></Strong> (A Study of Pembrolizumab [MK-3475] in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma [MK-3475-051/KEYNOTE-051])<Strong>:</Strong>
This is a two-part study of pembrolizumab in pediatric participants who have either advanced melanoma or a programmed cell death ligand 1 (PD-L1)-positive advanced, relapsed, or refractory solid tumor or lymphoma. Part 1 will find the maximum tolerated dose/maximum administered dose, confirm the dose, and find the recommended phase II dose for pembrolizumab therapy. Part 2 will further evaluate the safety and efficacy of the phase II dose recommended for pediatric patients.</ListItem></ItemizedList></SummarySection><SummarySection id="_2355"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Latest Updates to This Summary (04/03/2025)</Title><Para id="_2356">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.</Para><Para id="_2507"><Strong><SummaryRef href="CDR0000800109#_706" url="/types/skin/hp/child-melanoma-treatment-pdq">Diagnostic Evaluation</SummaryRef></Strong></Para><Para id="_2508">Added <SummaryRef href="CDR0000800109#_1521" url="/types/skin/hp/child-melanoma-treatment-pdq">text</SummaryRef> to state that partial shave biopsy may compromise microstaging and is associated with more invasive, definitive surgical treatments (cited Arjunan et al. as reference 5).</Para><Para id="_2509">Added <SummaryRef href="CDR0000800109#_2506" url="/types/skin/hp/child-melanoma-treatment-pdq">text</SummaryRef> to state that a Children's Oncology Group–led panel of experts from different specialties have developed recommendations for the diagnostic evaluation and surgical management of cutaneous melanomas, atypical Spitz tumors, and non-Spitz melanocytic tumors (cited Sargen et al. as reference 14).</Para><Para id="_2510"><Strong><SummaryRef href="CDR0000800109#_710" url="/types/skin/hp/child-melanoma-treatment-pdq">Treatment of Childhood Melanoma</SummaryRef></Strong></Para><Para id="_2511">Added <SummaryRef href="CDR0000800109#_2391" url="/types/skin/hp/child-melanoma-treatment-pdq">text</SummaryRef> to state that a Children's Oncology Group–led panel of experts from different specialties have developed recommendations for the diagnostic evaluation and surgical management of cutaneous melanomas, atypical Spitz tumors, and non-Spitz melanocytic tumors (cited Sargen et al. as reference 2).</Para><Para id="_2512">Added <SummaryRef href="CDR0000800109#_2282" url="/types/skin/hp/child-melanoma-treatment-pdq">text</SummaryRef> about the results of a retrospective review that identified 99 patients with melanoma who were treated with systemic therapy, 81 of whom received anti–PD-1 therapy (cited Mandalà et al. as reference 11).</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/pediatric-treatment">PDQ Pediatric Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000800109#_AboutThis_1" url="/types/skin/hp/child-melanoma-treatment-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="https://www.cancer.gov/publications/pdq">PDQ® Cancer Information for Health Professionals</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of pediatric melanoma. It is intended as a resource to inform and assist clinicians in the care of their patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/pediatric-treatment">PDQ Pediatric Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Childhood Melanoma Treatment are:</Para><ItemizedList Style="bullet"><ListItem>Denise Adams, MD (Children's Hospital Boston)</ListItem><ListItem>Karen J. Marcus, MD, FACR (Dana-Farber of Boston Children's Cancer Center and Blood Disorders Harvard Medical School)</ListItem><ListItem>William H. Meyer, MD</ListItem><ListItem>Paul A. Meyers, MD (Memorial Sloan-Kettering Cancer Center)</ListItem><ListItem>Thomas A. Olson, MD (Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta - Egleston Campus)</ListItem><ListItem>Arthur Kim Ritchey, MD (Children's Hospital of Pittsburgh of UPMC)</ListItem><ListItem>Carlos Rodriguez-Galindo, MD (St. Jude Children's Research Hospital)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Pediatric Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">PDQ® Pediatric Treatment Editorial Board. PDQ Childhood Melanoma Treatment. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="https://www.cancer.gov/types/skin/hp/child-melanoma-treatment-pdq">https://www.cancer.gov/types/skin/hp/child-melanoma-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 31909946]</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="https://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov website can be found on our <ExternalRef xref="https://www.cancer.gov/contact">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the website’s <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>.</Para></SummarySection></SummarySection><DateFirstPublished>2019-12-23</DateFirstPublished><DateLastModified>2025-04-03</DateLastModified></Summary>
